Erlotinib and bevacizumab in newly diagnosed performance status 2 or elderly patients with nonsquamous non-small-cell lung cancer, a phase II study of the hoosier oncology group: LUN04-77

Clinical Lung Cancer

Volumn 14, Issue 3, 2013, Pages 224-229

  Riggs, Heather ^a,b   Jalal, Shadia I ^a,c,d   Baghdadi, Tareq Al ^a,e   Bhatia, Sumeet ^a,f   McClean, John ^a,g   Johnson, Cynthia ^a,c   Yu, Menggang ^a,h   Taber, David ^a,i   Harb, Wael ^a,j   Hanna, Nasser ^a,c,d  

^a Hoosier Oncology Group   (United States)

^b Reid Oncology Associates   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e IHA Hematology Oncology Consultants   (United States)

^f INDIANA UNIVERSITY HEALTH   (United States)

^g Department of Biostatistics ^*

^h UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

ⁱ Northern Indiana Cancer Research Consortium   (United States)

^j Horizon Oncology   (United States)

more..

Author keywords

Advanced; Biological therapy; First line; Nonsquamous NSCLC; Unselected population

Indexed keywords

BEVACIZUMAB; ERLOTINIB;

ABDOMINAL PAIN; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; COUGHING; DEHYDRATION; DEPRESSION; DIARRHEA; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRY SKIN; DUODENAL ULCER BLEEDING; DYSPEPSIA; DYSPNEA; EDEMA; EPISTAXIS; EYE DISEASE; FACE PAIN; FATIGUE; FEMALE; GERIATRIC PATIENT; HEART DISEASE; HEMOPTYSIS; HOARSENESS; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; LUNG INFILTRATE; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POST TREATMENT SURVIVAL; PROTEINURIA; SIDE EFFECT; STOMATITIS; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUINAZOLINES;

EID: 84879952863     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2012.09.004     Document Type: Article

References (43)

1. R.C. Lilenbaum, J. Cashy, T.A. Hensing Prevalence of poor performance status in lung cancer patients: implications for research J Thorac Oncol 3 2008 125 129
2. E. Dajczman, G. Kasymjanova, H. Kreisman Should patient-rated performance status affect treatment decisions in advanced lung cancer? J Thorac Oncol 3 2008 1133 1136
3. I.D. Schnadig, E.K. Fromme, C.L. Loprinzi Patient-physician disagreement regarding performance status is associated with worse survivorship in patients with advanced cancer Cancer 113 2008 2205 2214
4. C.G. Azzoli, S. Baker Jr., S. Temin American Society of Clinical Oncology Clinical Practice guideline update on chemotherapy for stage IV non-small-cell lung cancer J Clin Oncol 27 2009 6251 6266
5. C. Gridelli, A. Ardizzoni, T. Le Chevalier Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel Ann Oncol 15 2004 419 426
6. F.H. Blackhall, J. Bhosle, N. Thatcher Chemotherapy for advanced non-small cell lung cancer patients with performance status 2 Curr Opin Oncol 17 2005 135 139
7. F.A. Shepherd, J. Rodrigues Pereira, T. Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
8. D.M. Jackman, B.Y. Yeap, N.I. Lindeman Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer J Clin Oncol 25 2007 760 766
9. P.J. Hesketh, K. Chansky, A.J. Wozniak Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2 J Thorac Oncol 3 2008 1026 1031
10. V. Poindessous, D. Ouaret, K. El Ouadrani EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies Clin Cancer Res 17 2011 6522 6530
11. N. Schicher, V. Paulitschke, A. Swoboda Erlotinib and bevacizumab have synergistic activity against melanoma Clin Cancer Res 15 2009 3495 3502
12. A. Sandler, R. Herbst Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways Clin Cancer Res 12 2006 4421s 4425s
13. R.S. Herbst, D.H. Johnson, E. Mininberg Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer J Clin Oncol 23 2005 2544 2555
14. R.S. Herbst, V.J. O'Neill, L. Fehrenbacher Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer J Clin Oncol 25 2007 4743 4750
15. V.L. Keedy, S. Temin, M.R. Somerfield American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy J Clin Oncol 29 2011 2121 2127
16. T.S. Mok, Y.L. Wu, S. Thongprasert Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
17. M. Fukuoka, Y. Wu, S. Thongprasert Biomarker analysis and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) J Clin Oncol 29 2011 2866 2874
18. R. Rosell, E. Carcereny, R. Gervais Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 2012 239 246
19. C.Q. Zhu, G. da Cunha Santos, K. Ding Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 J Clin Oncol 26 2008 4268 4275
20. B.P. Schneider, M. Wang, M. Radovich Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100 J Clin Oncol 26 2008 4672 4678
21. B.P. Schneider, M. Radovich, K.D. Miller The role of vascular endothelial growth factor genetic variability in cancer Clin Cancer Res 15 2009 5297 5302
22. R.S. Herbst, R. Ansari, F. Bustin Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial Lancet 377 2011 1846 1854
23. M. Thomas, A. Reuss, J. Fischer Innovations: randomized phase II trial of erlotinib (E)/bevacizumab (B) compared with cisplatin (P)/gemcitabine (G) plus B in first-line treatment of advanced nonsquamous (NS) non-small cell lung cancer (NSCLC) J Clin Oncol 29 Suppl 2011 Abstract 7504
24. A. Inoue, K. Kobayashi, K. Usui First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy J Clin Oncol 27 2009 1394 1400
25. D. Camidge, Y. Bang, E. Kwak Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC) J Clin Oncol 29 Suppl 2011 Abstract 2501
26. C. Gridelli, F. Ciardiello, R. Feld International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small-cell lung cancer (aNSCLC): the TORCH trial J Clin Oncol 28 Suppl 2010 Abstract 7508
27. R. Lilenbaum, R. Axelrod, S. Thomas Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 J Clin Oncol 26 2008 863 869
28. S. Lee, R. Rudd, I. Khan TOPICAL: randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy J Clin Oncol 28 Suppl 2010 Abstract 7504
29. C.J. Langer, K.J. O'Byrne, M.A. Socinski Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer J Thorac Oncol 3 2008 623 630
30. R. Lilenbaum, V.M. Villaflor, C. Langer Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials J Thorac Oncol 4 2009 869 874
31. R. Lilenbaum, M. Zukin, J. Rodrigues-Pereira A randomized phase III trial of single-agent pemetrexed (P) versus carboplatin and pemetrexed (CP) in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2 J Clin Oncol 30 Suppl 2012 Abstract 7506
32. S.P. Blagden, S.C. Charman, L.D. Sharples Performance status score: do patients and their oncologists agree? Br J Cancer 89 2003 1022 1027
33. V. Gebbia, D. Galetta, F. De Marinis Non small cell lung cancer patients with ECOG PS2: unsolved questions and lessons from clinical trials Ann Oncol 16 Suppl 4 2005 iv123 iv131
34. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The elderly Lung Cancer Vinorelbine Italian Study Group J Natl Cancer Inst 91 1999 66 72
35. C. Gridelli, F. Perrone, C. Gallo Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the multicenter Italian lung cancer in the elderly study (MILES) phase III randomized trial J Natl Cancer Inst 95 2003 362 372
36. E. Quoix, G. Zalcman, J. Oster Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial Lancet 378 2011 1079 1088
37. S. Wang, M.L. Wong, N. Hamilton Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans J Clin Oncol 30 2012 1447 1455
38. G. Frasci, V. Lorusso, N. Panza Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer J Clin Oncol 18 2000 2529 2536
39. T.R. Asmis, K. Ding, L. Seymour Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials J Clin Oncol 26 2008 54 59
40. M. Extermann, J. Overcash, G.H. Lyman Comorbidity and functional status are independent in older cancer patients J Clin Oncol 16 1998 1582 1587
41. C. Langer, S. Li, J. Schiller Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599 J Clin Oncol 25 2007 418 423
42. D. Pham, M.G. Kris, G.J. Riely Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas J Clin Oncol 24 2006 1700 1704
43. S.P. D'Angelo, M.C. Pietanza, M.L. Johnson Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas J Clin Oncol 29 2011 2066 2070